Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Feb 24 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Pitavastatin Tablets in various strengths. The approval allows Zydus to manufacture the drug at its facility in Moraiya, which is indicated for managing cholesterol levels in patients. The press release highlights that Pitavastatin had significant annual sales in the United States, indicating its market potential.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 24, 2023, titled "Zydus receivesfinal approval from the USFDA for Pitavastatin Tablets, 1 mg, 2 mg, and 4 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases